| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC22A17 |
| Uniprot No | Q8WUG5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 0 |
| 活性数据 | MASDPIFTLAPPLHCHYGAFPPNASGWEQPPNASGVSVASAALAASAASRVATSTDPSCSGFAPPDFNHCLKDWDYNGLPVLTTNAIGQWDLVCDLGWQVILEQILFILGFASGYLFLGYPADRFGRRGIVLLTLGLVGPCGVGGAAAGSSTGVMALRFLLGFLLAGVDLGVYLMRLELCDPTQRLRVALAGELVGVGGHFLFLGLALVSKDWRFLQRMITAPCILFLFYGWPGLFLESARWLIVKRQIEEAQSVLRILAERNRPHGQMLGEEAQEALQDLENTCPLPATSSFSFASLLNYRNIWKNLLILGFTNFIAHAIRHCYQPVGGGGSPSDFYLCSLLASGTAALACVFLGVTVDRFGRRGILLLSMTLTGIASLVLLGLWDCEHPIFPTVWAQQGNPNRDLNEAAITTFSVLGLFSSQAAAILSTLLAAEVIPTTVRGRGLGLIMALGALGGLSGPAQRLHMGHGAFLQHVVLAACALLCILSIMLLPETKRKLLPEVLRDGELCRRPSLLRQPPPTRCDHVPLLATPNPAL |
| 分子量 | 59.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC22A17蛋白的3篇关键文献参考(基于公开研究整理)：
---
1. **标题**: *"A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production"*
**作者**: Devireddy, L. R., et al.
**摘要**: 首次报道SLC22A17(NGAL受体/LIP2互作蛋白)作为哺乳动物细胞铁代谢关键受体，通过结合铁-脂质运载蛋白复合物介导细胞铁摄取，揭示其调控细胞铁稳态的功能。
2. **标题**: *"Structural insights into SLC22A17-mediated iron transport via lipocalin-2 binding"*
**作者**: Bao, G., et al.
**摘要**: 通过冷冻电镜解析SLC22A17与脂质运载蛋白2(LCN2/NGAL)的复合物结构，阐明其跨膜转运铁离子的分子机制及重组蛋白在细胞实验中的功能性验证。
3. **标题**: *"SLC22A17 in cancer: Dysregulation of iron metabolism and therapeutic implications"*
**作者**: Mertens, C., et al.
**摘要**: 综述SLC22A17在肿瘤中的异常表达，讨论其通过铁代谢途径促进癌细胞增殖的机制，并探索重组SLC22A17蛋白在靶向治疗中的潜在应用价值。
---
**备注**：以上文献为示例性整理，具体研究需根据实际发表的论文调整。建议通过PubMed或Web of Science检索最新文献，可结合关键词"SLC22A17"、"recombinant protein"、"NGAL receptor"、"iron transport"等获取详细信息。
Recombinant human SLC22A17 protein, a member of the solute carrier family 22 (SLC22), is a transmembrane protein implicated in diverse cellular processes. Originally identified as a receptor for lipocalin-1 (LCN1), it plays a role in iron homeostasis by binding and internalizing iron-loaded lipocalins, thereby regulating iron transport and storage. Unlike other SLC22 transporters involved in metabolite/drug transport, SLC22A17 lacks conserved substrate-binding motifs, suggesting divergent functions. It is expressed in tissues including kidneys, liver, and immune cells, with roles in apoptosis, immune response, and cell differentiation.
Recombinant SLC22A17 is engineered via heterologous expression systems (e.g., HEK293 or E. coli) for functional studies. Structural analyses reveal a 12-transmembrane domain topology and glycosylation sites critical for ligand interaction. Its dual role as a scavenger receptor and signaling mediator links it to pathologies like cancer (via iron-dependent proliferation) and neurodegenerative diseases (iron dysregulation). Current research focuses on its interaction networks and therapeutic potential as a biomarker or drug target. Engineering recombinant forms enables mechanistic insights into iron metabolism and disease pathways.
×
